34 related articles for article (PubMed ID: 38451968)
21. Genetics and biology of prostate cancer.
Wang G; Zhao D; Spring DJ; DePinho RA
Genes Dev; 2018 Sep; 32(17-18):1105-1140. PubMed ID: 30181359
[TBL] [Abstract][Full Text] [Related]
22. The Charlson Comorbidity Index in Registry-based Research.
Brusselaers N; Lagergren J
Methods Inf Med; 2017; 56(5):401-406. PubMed ID: 29582935
[TBL] [Abstract][Full Text] [Related]
23. The Surgical Management of Prostate Cancer.
Sebesta EM; Anderson CB
Semin Oncol; 2017 Oct; 44(5):347-357. PubMed ID: 29580436
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer incidence and mortality in Navarre (Spain).
Etxeberria J; Guevara M; Moreno-Iribas C; Burgui R; Delfrade I; Floristán Y; Montesino M; Ardanaz E
An Sist Sanit Navar; 2018 Apr; 41(1):9-15. PubMed ID: 29358783
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models.
Sanghera S; Coast J; Martin RM; Donovan JL; Mohiuddin S
BMC Cancer; 2018 Jan; 18(1):84. PubMed ID: 29347916
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers in prostate cancer - Current clinical utility and future perspectives.
Kretschmer A; Tilki D
Crit Rev Oncol Hematol; 2017 Dec; 120():180-193. PubMed ID: 29198331
[TBL] [Abstract][Full Text] [Related]
27. Histopathology of Prostate Cancer.
Humphrey PA
Cold Spring Harb Perspect Med; 2017 Oct; 7(10):. PubMed ID: 28389514
[TBL] [Abstract][Full Text] [Related]
28. Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography.
Rebbeck TR
Semin Radiat Oncol; 2017 Jan; 27(1):3-10. PubMed ID: 27986209
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic and Therapeutic Strategies for Prostate Cancer.
Nguyen-Nielsen M; Borre M
Semin Nucl Med; 2016 Nov; 46(6):484-490. PubMed ID: 27825428
[TBL] [Abstract][Full Text] [Related]
30. An incidence model of the cost of advanced prostate cancer in Spain.
Hart WM; Nazir J; Baskin-Bey E
J Med Econ; 2014 Feb; 17(2):125-31. PubMed ID: 24350997
[TBL] [Abstract][Full Text] [Related]
31. Trends in prostate cancer survival in Spain: results from population-based cancer registries.
Marcos-Gragera R; Salmerón D; Izarzugaza I; Ardanaz E; Serdà BC; Larrañaga N; San Román E; Navarro C; Chirlaque MD
Clin Transl Oncol; 2012 Jun; 14(6):458-64. PubMed ID: 22634535
[TBL] [Abstract][Full Text] [Related]
32. Use of the Charlson combined comorbidity index to predict postradiotherapy quality of life for prostate cancer patients.
Wahlgren T; Levitt S; Kowalski J; Nilsson S; Brandberg Y
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):997-1004. PubMed ID: 20932681
[TBL] [Abstract][Full Text] [Related]
33. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK.
Fourcade RO; Benedict A; Black LK; Stokes ME; Alcaraz A; Castro R
BJU Int; 2010 Jan; 105(1):49-56. PubMed ID: 20132102
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer in Spain: A retrospective database analysis of hospital incidence and the direct medical costs.
Darbà J; Ascanio M
PLoS One; 2024; 19(3):e0298764. PubMed ID: 38451968
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
